We are writing in response to 2 Letters to the Editor, both of which discussed our commentary, entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution." We appreciate the thoughtful responses to our commentary, and we invite further dialogue about this important subject. Both letters emphasized the importance in engaging in thoughtful research approaches to ensure the safety of individuals who are administered psychedelics.
View Article and Find Full Text PDFBackground: Multimorbidity is a growing burden in our ageing society and is associated with perioperative morbidity and mortality. Despite several modifications to the ASA physical status classification, multimorbidity as such is still not considered. Thus, the aim of this study was to quantify the burden of comorbidities in perioperative patients and to assess, independent of ASA class, its potential influence on perioperative outcome.
View Article and Find Full Text PDFImportance: As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integration into mainstream medical practice.
Objective: To identify key ethics and policy issues related to the eventual integration of psychedelic therapies into clinical practice.
Evidence Review: From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists convened at the Banbury Center at Cold Spring Harbor Laboratory.